MTA2 and cancer: Building upon our previous work on aptamer-functionalized liposomes and lipid nanoparticles for cancer-targeted delivery [33,34,35], we developed an AS1411-conjugated liposomal siRNA platform (AS1411-Lipm[siRNA]) aimed at selectively silencing MTA2 in nucleolin-overexpressing pancreatic ductal adenocarcinoma (PDAC) cells, a malignancy highly resistant to conventional therapy (Figure 1B).